Zum Inhalt springen

Class Action Lawsuit Against CrowdStrike

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 30, 2024 to file lead plaintiff applications in a securities class action lawsuit against CrowdStrike Holdings, Inc. (the “Company”) (NasdaqGS: CRWD), if they purchased the Company’s Class A shares between November 29, 2023 and July 29, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Texas. Get Help CrowdStrike investors should visit us at https://claimsfiler.com/cases/nasdaq-crwd/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options. About the Lawsuit CrowdStrike and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. On July 19, 2024, an update pushed by the Company caused global outages for millions of users… 

more »Class Action Lawsuit Against CrowdStrike

Class Action Lawsuit Against Moderna

Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Moderna, Inc. (NASDAQ: MRNA) securities between January 18, 2023 and June 25, 2024. Moderna is a biotechnology company that discovers, develops, and commercializes messenger RNA (“mRNA”) therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the U.S., Europe, and internationally. The Allegations: Robbins LLP is Investigating Allegations that Moderna, Inc. (MRNA) Misled Investors Regarding the Efficacy of its RSV Vaccine According to the complaint, the Company’s products include, inter alia, mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (“RSV”) vaccine, intended to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. Plaintiff alleges that during the class period, defendants failed to disclose that:… 

more »Class Action Lawsuit Against Moderna

Vaxcyte Announces Pricing of $1.3 Billion Public Offering

Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 10,194,175 shares of common stock and pre-funded warrants to purchase 2,427,184 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $103.00 per share, and the pre-funded warrants are being sold at a public offering price of $102.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $1.3 billion, before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants. The offering is expected… 

more »Vaxcyte Announces Pricing of $1.3 Billion Public Offering

Squalene Market Growing at Exponential CAGR by 2030

The global squalene industry generated $114.5 million in 2020, and is estimated to reach $241.6 million by 2030, witnessing a CAGR of 7.8% from 2021 to 2030. The squalene market is experiencing robust growth due to rising demand in cosmetics and pharmaceuticals for its moisturizing and anti-aging properties. Increased awareness of natural and sustainable ingredients is driving market expansion. Additionally, innovations in extraction techniques and applications are broadening its industry uses. Allied Market Research published a report, titled, „Squalene Market by Source (Animal, Vegetable, and Synthetic Biotechnology), End Use Industry (Cosmetics, Nutraceuticals, and Healthcare): Global Opportunity Analysis and Industry Forecast, 2021–2030.“ Squalene is a colorless, oily triterpene hydrocarbon that is found in many animals and plants, including sharks, olives, and sugarcane. Drivers, Restraints, and Opportunities:Rise of the cosmetics industry, surge in value and potential of dietary supplements, and usage of… 

more »Squalene Market Growing at Exponential CAGR by 2030


Real World Data Supports Lenire Tinnitus Treatment

The first real-world analysis of tinnitus patients treated with Lenire in the United States has been submitted to a journal for peer-review and is now available on an online pre-print server for health services, medRxiv.Real-world results are consistent with Lenire’s large-scale clinical trial results.91.5% of patients experienced clinically meaningful reduction in tinnitus after 12-weeks of treatment with Lenire.89.2% of patients indicated they benefited from treatment with Lenire.220 patient treatment results were analyzed for the review making the paper one of the largest real-world analyses of tinnitus patients ever conducted.

Aufwendungen von Arztpraxen stark gestiegen

Die Aufwendungen der Arztpraxen in Deutschland haben im Jahr 2022 um 11,0 Prozent gegenüber dem Vorjahr zugenommen. In einem Umfeld stark gestiegener Verbraucherpreise erhöhten sich die durchschnittlichen Aufwendungen je Arztpraxis im Jahr 2022 auf 466.000 Euro (2021: 420.000 Euro), teilte das Statistische Bundesamt am Dienstag mit. Zu den Arztpraxen zählen Einzelpraxen, fachgleiche sowie fachübergreifende Berufsausübungsgemeinschaften […] Aufwendungen von Arztpraxen stark gestiegen

Mehr als jedes zweite Unternehmen wird Ransomware-Opfer

Mehr als jedes zweite Unternehmen in Deutschland ist in den vergangenen zwölf Monaten Opfer von Ransomware geworden. Das geht aus einer am Mittwoch veröffentlichten Umfrage des IT-Branchenverbands hervor. Demnach wurden sechs von zehn Unternehmen zuletzt auf diese Weise angegriffen, 29 Prozent hatten dadurch keinen Schaden, bei 31 Prozent ist ein Schaden entstanden – etwa durch […] Mehr als jedes zweite Unternehmen wird Ransomware-Opfer

Wissenschaftsmarkt am 7. und 8. September auf dem Gutenbergplatz

Mitten in Mainz wird Wissenschaft am 7. und 8. September wieder lebendig. Der 22. Mainzer Wissenschaftsmarkt findet von 11 bis 18 Uhr auf dem Gutenbergplatz statt. Die Besucher erwartet ein vielseitiges Programm an Mitmachständen sowie ein Bühnenprogramm unter dem Motto „Mensch und Wachstum“. Von mittags bis abends stehen Wissenschaftler der Hochschulen und Universitäten sowie Forschungseinrichtungen… Wissenschaftsmarkt am 7. und 8. September auf dem Gutenbergplatz

Weltmeisterschaft für Transplantierte in Dresden

Dresden kann sich kommenden Sommer auf eine in Deutschland bis dato einmalige Weltmeisterschaft freuen.  Vom 17. bis 24. August 2025 werden die World Transplant Games (WTG 2025) in der Landeshauptstadt ausgetragen. Das Sportevent findet erstmals in seiner knapp 50-jährigen Geschichte in Deutschland statt. Rund 2.500 transplantierte Sportler aus 60 Nationen werden in Dresden erwartet. Erste Programmhighlights und prominente Gesichter stehen fest. 17 Sportarten in Dresden und Umgebung Die World Transplant Games, die unter dem Dachverband der World Transplant Games Federation stehen,  verstehen sich als Weltmeisterschaft für organtransplantierte Sportler, Lebendspender und Spenderfamilien. Für die 17 Sportarten – Medaillen werden in Leichtathletik, Bowling, Triathlon, Radrennen, 5-Kilometer-Lauf, Golf, Schwimmen, Fußball (6 gegen 6), Basketball (3 gegen 3), Volleyball, Tennis, Tischtennis, Petanque, Darts, Squash, Badminton und Bogenschießen vergeben – wurden neun Sportstätten ausgewählt. Unter anderem finden Wettkämpfe im Schwimmsportkomplex Freiberger Platz, auf der Golfanlage… 

more »Weltmeisterschaft für Transplantierte in Dresden

First FDA cleared digital treatment for generalized anxiety disorder

Big Health, a leading developer of digital mental health treatments, has been granted clearance by the U.S. Food and Drug Administration (FDA) for its digital therapeutic, DaylightRx. DaylightRx is a prescription device delivering Cognitive Behavioral Therapy and can be made available on the order of a licensed healthcare provider. DaylightRx is a digital therapeutic intended to treat generalized anxiety disorder (GAD) by improving a patient’s GAD symptoms as an adjunct to usual care in patients aged 22 years and older. DaylightRx is the first FDA-cleared digital treatment for generalized anxiety disorder. DaylightRx is an innovative digital formulation of cognitive behavioral therapy for GAD that teaches patients evidence-based techniques to change the thoughts and behaviors that maintain chronic worry and anxiety. DaylightRx includes interactive lessons on applied relaxation to reduce tension, stimulus control to decrease worry frequency, cognitive restructuring to break… 

more »First FDA cleared digital treatment for generalized anxiety disorder